GlassScriptPhysician profile
Luis M Benavides
NPI 1780656686
$2,043.88
in general payments reported to CMS, 2019-2025
29 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $34.64 · 2021: $164 · 2022: $291 · 2023: $452 · 2024: $355 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $543.26 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $267.24 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Viiv Healthcare Company | $177.00 | 2025 | Cabenuva |
| Bolton Medical INC | $130.12 | 2024 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Astrazeneca Pharmaceuticals LP | $114.74 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $100.00 | 2023 | |
| Mallinckrodt Hospital Products INC. | $74.77 | 2023 | Terlivaz |
| Merck Sharp & Dohme LLC | $64.62 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Esperion Therapeutics, INC. | $60.92 | 2021-2022 | |
| Amarin Pharma, INC. | $58.18 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $56.77 | 2023-2024 | Rexulti |
| Dexcom, INC. | $41.71 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $36.47 | 2022-2024 | |
| Amgen INC. | $32.69 | 2023 | Repatha, Otezla |
| Pfizer INC. | $29.37 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.47 | 2023 | Freestyle Libre 3 |
| Lundbeck LLC | $22.84 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $21.92 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.37 | 2019 | |
| Corcept Therapeutics | $20.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.84 | 2019 | |
| Ani Pharmaceuticals, INC. | $19.80 | 2025 | Purified Cortrophin Gel |
| Nestle Healthcare Nutrition INC. | $18.08 | 2021 | |
| Aimmune Therapeutics, INC. | $17.84 | 2024 | |
| Melinta Therapeutics, LLC | $17.32 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2023 | Xifaxan |
| Glaxosmithkline, LLC. | $13.76 | 2025 | Shingrix, Bexsero |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Eisai INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Benavides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.